WuXi Biologics to Increase Manufacturing Capacity in Massachusetts
- None.
- None.
- The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the
U.S. - The site is expected to employ 250 people when fully operational.
In response to global clients' increasing demand for contract manufacturing services, the
WuXi Biologics currently employs over 400 people in the
Dr. Chris Chen, CEO of WuXi Biologics, noted, "The new commercial capacity in
Last year, WuXi Biologics launched its first Boston Research Service Center, marking its fourth site in the
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Business
info@wuxibiologics.com
Media:
PR@wuxibiolgics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-to-increase-manufacturing-capacity-in-massachusetts-302028322.html
SOURCE WuXi Biologics
FAQ
What is WuXi Biologics' ticker symbol?
What is the total manufacturing capacity increase for WuXi Biologics' facility in Worcester, Massachusetts?
How many new jobs will be created by WuXi Biologics' expansion?
When is the GMP release expected for WuXi Biologics' Worcester facility?